Precipio Diagnostics is a small healthcare company focused on cancer diagnostics, particularly for hematologic cancers like leukemia and lymphoma. Precipio operates two divisions. The first, Pathology Services, is the core revenue driver today: Precipio runs two clinical labs in New Haven, Connecticut, receiving blood and bone marrow samples from oncologists, hospitals, and clinics across more than 20 states, then analyzing those samples using molecular diagnostics and cytogenetics to deliver pathology reports to physicians. Precipio bills insurance companies, Medicare, and private payers per test performed, with government programs accounting for roughly 40% of revenue. The second division, Products, is the growth engine: Precipio develops and sells proprietary diagnostic kits to other labs, enabling those labs to run specialized tests in-house. The two commercial products are HemeScreen, a suite of RT-PCR panels for genetic mutation testing in blood cancers positioned between expensive next-generation sequencing and simpler single-gene tests, and IV-Cell, a cell culture media that simultaneously cultures all four hematopoietic cell lineages, reducing false negatives from incorrect lineage selection. Products revenue is recurring, as labs buy kits on an ongoing basis, and carries higher potential margins than Pathology since Precipio does not perform the testing itself. The two divisions are integrated: the Pathology labs provide continuous access to real clinical samples, allowing Precipio to develop and validate new products at low incremental cost, which management describes as a "self-funded R&D" model.